BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
News Jun 25, 2013
BioFocus has announced that it has received a Rapid Response Innovation Award from The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
BioFocus will use the investment to develop a high-throughput, high-content assay platform to support the discovery of targets and agents that break the pathogenic loop between glucocerebrosidase (GBA) and a-synuclein, considered to be a major mechanism leading to Parkinson’s disease.
The project is further supported by a new collaboration between BioFocus and Professor Tony Schapira, Institute of Neurology, University College London, a renowned medical researcher in Parkinson’s disease.
Prof. Tony Schapira commented: “The link between mutations in the GBA gene and Parkinson’s disease has been affirmed by multiple clinical studies. The development of a disease-relevant cell model system to support drug discovery on this mechanism will be a critical asset to the Parkinson’s disease research community.”
Prof. Julie Frearson, Senior Director Scientific Alliances and Translational Research, BioFocus, said: “We are delighted and honored to receive this grant. This funding will allow BioFocus to continue tackling novel and challenging therapeutic mechanisms in Parkinson’s disease.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019